Nuo Therapeutics Q1 revenues up 169% YoY to $1.3M; operating loss narrows

Nuo Therapeutics, Inc.

Total revenue $1.3M, including $1.22M product sales, up 169% YoY and 20% sequential.
Aurix branded product revenue rose over 30% sequentially versus Q4 2025.
Net operating loss improved to $446,000 from $745,000 in Q1 2025.
Entered $1.0M Loan and Security Agreement to fund growth as company approaches breakeven.
CEO cites strong Aurix demand and favorable Medicare reimbursement shift for autologous PRP.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.